How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,360 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS

The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02673632 Recruitment Status : Unknown Verified February 2016 by Ahmed Mohamed Bahaa Eldin Ahmed, Ain Shams

2016 Clinical Trials

142. Roles of Hippocampal Somatostatin Receptor Subtypes in Stress Response and Emotionality. Full Text available with Trip Pro

Roles of Hippocampal Somatostatin Receptor Subtypes in Stress Response and Emotionality. Altered brain somatostatin functions recently appeared as key elements for the pathogenesis of stress-related neuropsychiatric disorders. The hippocampus exerts an inhibitory feedback on stress but the mechanisms involved remain unclear. We investigated herein the role of hippocampal somatostatin receptor subtypes in both stress response and behavioral emotionality using C57BL/6, wild type and sst2 or sst4 (...) and antidepressive effects through distinct mechanisms. Such results are to be accounted for in development of pathway-specific somatostatin receptor agents in the treatment of hypercortisolism (Cushing's disease) and stress-related neuropsychiatric disorders.

2016 Neuropsychopharmacology

143. CADTH Therapeutic Review Clinical and Economic Overview. Biological Response Modifier Agents for Adults with Rheumatoid Arthritis

CADTH Therapeutic Review Clinical and Economic Overview. Biological Response Modifier Agents for Adults with Rheumatoid Arthritis Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé Supporting Informed Decisions CADTH Therapeutic review Clinical and Economic Overview: Biological Response Modifier Agents for Adults with Rheumatoid Arthritis July 2010* *An amendment was made in November 2010 Therapeutic Review CLINICAL (...) AND ECONOMIC OVERVIEW Biological Response Modifier Agents for Adults with Rheumatoid Arthritis July 2010 * * An amendment was made in November 2010 This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). The report contains a comprehensive review of the existing public literature, studies, materials, and other information and documentation (collectively the ?source documentation?) available to CADTH at the time of report preparation, and was guided by expert input

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

144. Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02467400 Recruitment Status : Completed First Posted : June 10, 2015 Last Update Posted : February 6, 2019 Sponsor: Mayo Clinic Information provided by (Responsible

2015 Clinical Trials

145. Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery

Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02549768 Recruitment Status : Unknown Verified October 2016 by Pontificia Universidad Catolica de Chile. Recruitment status was: Recruiting First Posted

2015 Clinical Trials

146. Cushing Syndrome

or in those receiving estrogen therapy, but diurnal variation is normal in these patients. Serum ACTH measurement ACTH levels are measured to determine the cause of Cushing syndrome. Undetectable levels, both basally and particularly in response to corticotropin -releasing hormone (CRH), suggest a primary adrenal cause. High levels suggest a pituitary cause or an ectopic source. If ACTH is detectable, provocative tests help differentiate Cushing disease from ectopic ACTH syndrome, which is rarer (...) . In response to high-dose dexamethasone (2 mg po q 6 h for 48 h), the 9 am serum cortisol falls by > 50% in most patients with Cushing disease but infrequently in those with ectopic ACTH syndrome. Conversely, ACTH rises by > 50% and cortisol rises by 20% in response to human or ovine-sequence CRH (100 mcg IV or 1 mcg/kg IV) in most patients with Cushing disease but very rarely in those with ectopic ACTH syndrome (see Table: ). An alternative approach to localization, which is more accurate but more

2013 Merck Manual (19th Edition)

147. Prediction of High Ovarian Response After Assisted Reproductive Techniques

Prediction of High Ovarian Response After Assisted Reproductive Techniques Prediction of High Ovarian Response After Assisted Reproductive Techniques - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Prediction of High Ovarian Response After Assisted Reproductive Techniques (HighART) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02358421 Recruitment Status : Unknown Verified January 2015 by Instituto de Investigacion Sanitaria La Fe. Recruitment status was: Recruiting First Posted : February 9, 2015

2014 Clinical Trials

148. Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

of saved studies (100). Please remove one or more studies before adding more. Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01371565 Recruitment Status : Completed First Posted : June 13 (...) , 2011 Results First Posted : November 20, 2013 Last Update Posted : March 18, 2014 Sponsor: Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study Description Go to Brief Summary: This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when given

2011 Clinical Trials

149. Effects of Hormone Stimulation on Brain Scans for Cushing s Disease

Stimulation on Brain Scans for Cushing s Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01459237 Recruitment Status : Completed First Posted : October 25, 2011 Last Update Posted : June 14, 2018 Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Information provided (...) by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) ) Study Details Study Description Go to Brief Summary: Background: Cushing s disease can be caused by a tumor of the pituitary gland, a small gland about the size of a pea located at the base of the brain. These tumors produce high levels of hormones, which cause obesity, diabetes, and growth problems. The cure for this type of Cushing s disease is to have surgery

2011 Clinical Trials

150. Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?

number of saved studies (100). Please remove one or more studies before adding more. Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? (DXM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01504555 Recruitment Status : Unknown (...) Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2011 Clinical Trials

151. Cushing and the treatment of brain wounds during World War I. (Abstract)

at the time and eventually, for some, it was Cushing who was responsible for lowering the postoperative mortality rate of brain wounds during World War I. As the decades passed he was eventually credited as the "originator of brain wound care." This report shows that these attributions are misplaced. Cushing merely followed the enlightened surgical precepts of the time developed by Continental (European) surgeons. It also examines Cushing's writings to ascertain how these misperceptions concerning his (...) Cushing and the treatment of brain wounds during World War I. Harvey Cushing, perhaps the most important founder of American neurosurgery, was an Army neurosurgeon in France from 1917 to 1918. Over a 3-month period in 1917 he and his team operated on 133 soldiers with a brain wound. The operative mortality rate for their last 45 patients was 29%, considerably lower than the usual postoperative mortality rate of approximately 50% for those with a brain wound. This accomplishment was lauded

2011 Journal of Neurosurgery

152. The Postoperative Basal Cortisol and CRH Tests for Prediction of Long-Term Remission from Cushing's Disease after Transsphenoidal Surgery. Full Text available with Trip Pro

The Postoperative Basal Cortisol and CRH Tests for Prediction of Long-Term Remission from Cushing's Disease after Transsphenoidal Surgery. Selective adenomectomy via transsphenoidal surgery induces remission of Cushing's disease (CD) in most patients. Although an undetectable postoperative serum cortisol (<2 μg/dl) has been advocated as an index of remission, there is no consensus on predictors of recurrence.We hypothesized that patients with subnormal cortisol (2-4.9 μg/dl) might achieve long (...) -term remission and that postoperative responses to CRH might predict recurrence.We prospectively studied CD patients with initial remission after adenomectomy or hemihypophysectomy (n = 14). Long-term recurrence (n = 39) or remission (n = 293) was assigned by laboratory results, glucocorticoid dependence, or patient survey at a mean of 10.6 yr after surgery.Postoperatively, morning cortisol was measured on d 3-5, and cortisol and ACTH responses to ovine CRH were assessed around d 10.Follow-up

2011 Journal of Clinical Endocrinology and Metabolism

153. Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery. Full Text available with Trip Pro

Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery. To describe the sequence of hormonal changes during recurrence of Cushing's disease (CD) after successful transsphenoidal surgery (TSS).Retrospective study in a single center.We studied 101 of the 127 patients treated by TSS for CD between 1996 and 2009, who had hypocortisolism or eucortisolism for at least 3 months post-TSS. We arbitrarily defined 'overt recurrence', as presence (...) , median 43, range 7-94 vs mean 21.5 months, median 17, range 3-61, P=0.05), in patients with early post-TSS hypocortisolism compared with those with eucortisolism. Increase in midnight cortisol occurred in a mean time of 38.2 months, while UC elevation was observed at 50.6 months. Vasopressin analogs and CRH tests were eventually positive in 85 and 93% of all patients respectively; a positive response to one of the two dynamic tests preceded the increase in midnight cortisol or UC in 71 and 64

2011 European Journal of Endocrinology

154. Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma

of saved studies (100). Please remove one or more studies before adding more. Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details (...) . ClinicalTrials.gov Identifier: NCT01382420 Recruitment Status : Recruiting First Posted : June 27, 2011 Last Update Posted : April 4, 2019 See Sponsor: Samsung Medical Center Collaborators: Asan Medical Center Severance Hospital Konkuk University Medical Center Information provided by (Responsible Party): Jae Hyeon Kim, Samsung Medical Center Study Details Study Description Go to Brief Summary: Objective: To determine the metabolic effects of the adrenalectomy in subclinical Cushing's syndrome of adrenal

2011 Clinical Trials

155. Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

studies before adding more. Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01374906 Recruitment Status : Completed First Posted : June 16, 2011 Results First Posted : April 11, 2018 Last Update Posted : May 22 (...) , 2018 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease. Condition or disease Intervention/treatment Phase Cushing's Disease Drug: pasireotide LAR Drug: SOM230 LAR 30 mg Drug: SOM230

2011 Clinical Trials

156. Safety and Efficacy of LCI699 in Cushing's Disease Patients.

in Cushing's Disease Patients. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01331239 Recruitment Status : Active, not recruiting First Posted : April 8, 2011 Last Update Posted : November 7, 2018 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis (...) Safety and Efficacy of LCI699 in Cushing's Disease Patients. Safety and Efficacy of LCI699 in Cushing's Disease Patients. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of LCI699

2011 Clinical Trials

157. Endogenous ACTH Concentration-Cortisol Secretion Dose Analysis Unmasks Decreased ACTH Potency in Cushing's Disease with Restoration after Successful Pituitary Adenomectomy. Full Text available with Trip Pro

· min, vs. controls, 21 ± 2.3 nmol/liter · min (P <0.0001), and cured patients, 15 ± 3.2 nmol/liter · min (NS vs. controls)]. Sensitivity to endogenous ACTH did not differ among the three groups.The adrenal gland in Cushing's disease exhibits decreased responsiveness to submaximal ACTH drive and amplified efficacy, with unchanged sensitivity. These target-gland abnormalities are reversible in long-term remission after pituitary surgery. (...) Endogenous ACTH Concentration-Cortisol Secretion Dose Analysis Unmasks Decreased ACTH Potency in Cushing's Disease with Restoration after Successful Pituitary Adenomectomy. The relationship between circulating ACTH levels and cortisol secretion in Cushing's disease is not precisely known.Chronic ACTH hyperstimulation leads to decreased adrenal potency and is restored after normalization of ACTH secretion.Subjects included 20 patients with Cushing's disease, eight patients in long-term remission

2011 Journal of Clinical Endocrinology and Metabolism

158. Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01876368 Recruitment Status : Completed First Posted : June

2013 Clinical Trials

159. Best African American Response to Asthma Drugs

Best African American Response to Asthma Drugs Best African American Response to Asthma Drugs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Best African American Response to Asthma Drugs (BARD) The safety (...) and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01967173 Recruitment Status : Completed First Posted : October 22, 2013 Results First Posted : November 15, 2018 Last Update Posted : November 15, 2018 Sponsor: Milton S. Hershey Medical Center Collaborator: National Heart, Lung, and Blood Institute (NHLBI) Information

2013 Clinical Trials

160. ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01984268 Recruitment Status : Unknown Verified August 2016 by Richard C. Chou, Dartmouth-Hitchcock Medical

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>